Ak. Andreassen et al., LEVELS OF CIRCULATING ADHESION MOLECULES IN CONGESTIVE-HEART-FAILURE AND AFTER HEART-TRANSPLANTATION, The American journal of cardiology, 81(5), 1998, pp. 604-608
Recent reports suggest a role for immunologic and inflammatory process
es in the pathogenesis of congestive heart failure (CHF) and accelerat
ed coronary artery disease (CAD) after heart transplantation (HT), The
interaction between endothelial cells, leukocytes, and platelets invo
lving various adhesion molecules may be of particular importance, We t
herefore measured serum levels of soluble(s) vascular cell adhesion mo
lecule-1 (VCAM-1), sP-selectin, and sE-selectin in 34 patients with se
vere CHF (23 with CAD and 11 with idiopathic dilated cardiomyopathy) a
nd in 20 healthy controls, Twenty of the patients were followed with s
erial measurements of these circulating adhesion molecules (CAMs) for
up to 2 years after HT, Levels of all 3 CAMs were significantly elevat
ed in patients with CHF compared with controls irrespective of the eti
ology of heart failure, with particularly high concentrations of sVCAM
-1, After HT, different patterns in CAMs were found over time, Whereas
there was a normalization of sE-selectin levels after HT, concentrati
ons of sVCAM-1 also declined, but without normalization, In contrast,
sP-selectin levels were persistently elevated, with the highest concen
trations at the end of the study period, The persistent elevation of s
P-selectin and the lack of normalization of sVCAM-1 levels were associ
ated with persistently raised serum levels of tumor necrosis factor-al
pha, and these findings were not related to either acute episodes of a
llograft rejection or intercurrent infections, These results support t
he notion that immunologic and inflammatory processes are important fe
atures of CHF. Furthermore, the persistently elevated levels of CAMs a
nd tumor necrosis factor-alpha found up to 2 years after HT may reflec
t a state of persistent immune activation in these patients, possibly
involved in the development of CAD after HT. (C) 1998 by Excerpta Medi
co, Inc.